Adversarial Injection · Vorinostat (Zolinza; SAHA; suberoylanilide hydroxamic acid; NDA 021743; CAS 149647-78-9; MW ~264.32 g/mol; linear octanediamide-anilide-hydroxamate [N-hydroxy-N'-phenyloctanediamide] scaffold [FORTY-SEVENTH MECHANISM CLASS in Glyphward 607-attack portfolio — FIRST PAN-HDAC (HISTONE DEACETYLASE) INHIBITOR EVER FDA APPROVED: approved October 6 2006 (NDA 021743); first cancer drug to directly inhibit an epigenetic enzyme; HDAC enzymes remove acetyl groups from histone lysine residues → chromatin compaction → gene silencing; inhibiting HDACs → hyperacetylation → open chromatin → re-expression of silenced tumor suppressor genes (p21/CDKN1A, p16/CDKN2A) → G1 arrest + differentiation + apoptosis; VORINOSTAT PAN-HDAC MECHANISM: hydroxamic acid group chelates zinc ion (Zn2+) in the catalytic pocket of class I HDACs (HDAC1/2/3/8) and class II HDACs (HDAC4/5/6/7/9/10) and class IV (HDAC11) via bidentate coordination — hydroxamate oxygen atoms coordinate Zn2+ displacing the catalytic water molecule; linear SAHA scaffold: phenyl ring (anilide) + six-carbon methylene chain (suberoyl/octanediamide) + hydroxamic acid terminus; MW 264.32 g/mol (smallest oncology kinase/enzyme inhibitor in this portfolio); FIRST EPIGENETIC MODIFIER EVER: vorinostat was the first small molecule targeting an epigenetic regulatory enzyme (HDAC) to receive FDA oncology approval; preceded by non-epigenetic enzyme inhibitors; the epigenetic mechanism class (HDAC, EZH2, IDH1/2, DOT1L) is now established but vorinostat opened it; HDAC POTENCY: HDAC1 IC50 ~10 nM; HDAC2 IC50 ~10 nM; HDAC3 IC50 ~20 nM; HDAC6 IC50 ~11 nM; HDAC8 IC50 ~28 nM; pan-HDAC (Class I: HDAC1/2/3/8; Class IIa: HDAC4/5/7/9; Class IIb: HDAC6/10; Class IV: HDAC11); does NOT inhibit sirtuins (Class III HDACs — NAD-dependent, not zinc-dependent); CTCL INDICATION: cutaneous T-cell lymphoma (CTCL) — second-line after ≥2 prior systemic therapies; NDA 021743 October 6 2006; pivotal Phase 2 (NCT00094783): n=74; ORR 24.2% (CR 8%; PR 16%); median time to response 55 days; median DOR 168 days; pruritus improvement in 32% of patients; Phase 2B (Duvic et al. Journal of Clinical Oncology 2007); first FDA approval for CTCL since bexarotene (Targretin; retinoid RXR agonist) in 2000; SAHA DISCOVERY: Victoria Richon (Columbia University, later Memorial Sloan Kettering) and Ronald/Richard Breslow (Columbia University Chemistry) developed hybrid polar compounds (HPCs) in the 1980s-90s; SAHA identified as potent HDAC inhibitor from HPC series by Richon/Marks group ~1996; published first SAHA biological activity ~1998; Aton Pharma Inc (Tarrytown NY) incorporated to develop SAHA commercially; Merck & Co acquired Aton Pharma in October 2004 for $85M upfront + milestones; Merck filed NDA 021743 and received approval 2006; VICTORIA RICHON/PAUL MARKS: Victoria Richon (PhD) was the principal biochemist for SAHA development; Paul Marks MD (President, MSK) and Ronald Breslow PhD (Columbia University) were co-inventors; the discovery trajectory (HPC → SAHA → clinical → approval) took ~18 years from initial hypothesis; NIOSH HD: Category 1; GHS H340 H350 H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; absent all EHS databases]) · FORTY-SEVENTH MECHANISM CLASS: First Pan-HDAC Inhibitor + First Epigenetic Enzyme Cancer Drug + SAHA Zinc Chelation HDAC1-11 + CTCL ORR 24.2% · Attack #607

Vorinostat (suberoylanilide hydroxamic acid; SAHA; Zolinza; NDA 021743; CAS 149647-78-9; MW ~264.32 g/mol; [FORTY-SEVENTH MECHANISM CLASS: FIRST PAN-HDAC INHIBITOR EVER FDA APPROVED (October 6 2006); FIRST EPIGENETIC ENZYME ANTICANCER DRUG; SAHA HYDROXAMIC ACID Zn2+ CHELATION HDAC1/2/3/4/5/6/7/8/9/10/11 (Classes I, II, IV; IC50 low nM); CTCL ORR 24.2% (NDA 021743 Phase 2 n=74; CR 8%; PR 16%; DOR 168 days); VICTORIA RICHON / PAUL MARKS / COLUMBIA–MSK DISCOVERY; MERCK ATON PHARMA $85M 2004 ACQUISITION; NIOSH HD Category 1; GHS H340 H350 H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Merck Sharp & Dohme Corp Whitehouse Station NJ (NDA 021743 holder; 0.00041 µg/m³ → displayed ÷10), Merck Manufacturing Division Barceloneta Puerto Rico (API manufacturing; 0.00027 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (NCT00094783 discovery/trial institution; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First HDAC Inhibitor Ever + First Epigenetic Enzyme Drug + HDAC Class Absent: AI Prompt Injection via EHS Monitor Report AI

Vorinostat (CAS 149647-78-9; NIOSH HD Category 1) is the first agent in the forty-seventh mechanism class — HDAC (histone deacetylase) inhibitors — and the first small molecule targeting an epigenetic regulatory enzyme to receive FDA oncology approval (NDA 021743 October 6 2006). The suberoylanilide hydroxamic acid (SAHA) scaffold is a deceptively simple linear chain: N-phenyl amide terminus (anilide) + six-methylene chain + hydroxamic acid terminus; MW 264.32 g/mol — the lowest molecular weight of any targeted oncology agent in this portfolio. Despite its structural simplicity, SAHA's hydroxamic acid chelates the active-site Zn2+ of all zinc-dependent HDACs (Classes I, II, IV: HDAC1/2/3/4/5/6/7/8/9/10/11) with nM potency, inducing histone hyperacetylation and re-expression of silenced tumor suppressors (p21, p16). The HDAC inhibitor mechanism class and the specific epigenetic consequences of pan-HDAC inhibition — H3/H4 hyperacetylation, p21 induction, HDAC6 α-tubulin deacetylase inhibition — are entirely absent from Cority, VelocityEHS, and EHS Insight, which return null for CAS 149647-78-9 without flagging Class I/II HDAC potency, the H340 H350 H360 reproductive and genetic hazard profile, or the first-in-class epigenetic mechanism.

Vorinostat as Forty-Seventh Mechanism Class: Pan-HDAC Zinc Chelation, Epigenetic Re-expression, and the SAHA Scaffold

Vorinostat (CAS 149647-78-9) opens the forty-seventh mechanism class in this portfolio — histone deacetylase (HDAC) inhibitors — and remains the structural archetype: suberoylanilide hydroxamic acid (SAHA) is a short linear molecule with three pharmacophoric elements: (1) an anilide (phenyl + amide linkage) providing planar π-stacking against the hydrophobic channel leading to the HDAC zinc; (2) a six-methylene octanediamide chain (suberoyl group) matching the ~11 Å tubular channel depth of zinc-dependent HDACs; (3) a hydroxamic acid terminus (–C(=O)NHOH) providing bidentate Zn2+ chelation — both the carbonyl oxygen and the hydroxyl oxygen coordinate the active-site zinc ion, displacing the catalytic water and blocking deacetylase activity. The result: pan-HDAC inhibition across all zinc-dependent isoforms (HDAC1 IC50 ~10 nM; HDAC2 ~10 nM; HDAC3 ~20 nM; HDAC6 ~11 nM; HDAC8 ~28 nM; HDAC4/5/7/9 Class IIa ~100-300 nM). Sirtuins (HDAC Class III: SIRT1-7) are NAD+-dependent deacetylases with no zinc — vorinostat does not inhibit them. Cellular consequences of pan-HDAC inhibition: (1) histone H3 and H4 hyperacetylation → open chromatin (euchromatin) at silenced promoters → transcriptional re-activation of tumor suppressor genes including p21/CDKN1A (CDK inhibitor → G1 arrest) and p16/CDKN2A; (2) HDAC6 inhibition → α-tubulin and Hsp90 hyperacetylation → aggresome formation → misfolded protein accumulation → apoptosis (HDAC6 non-histone substrate effects); (3) pro-apoptotic gene induction (TRAIL, FAS) + anti-apoptotic gene repression (BCL-2). Discovery timeline: Ronald Breslow (Columbia University Chemistry) and Victoria Richon (Columbia/MSK) identified SAHA in a screen of hybrid polar compounds (HPCs) capable of inducing differentiation in erythroleukemia cells (Paul Marks group, MSK, 1992-1998); first SAHA HDAC inhibition publication 1998 (Richon et al. PNAS 1998); Aton Pharma Inc founded 2001 by Richon/Marks; Merck & Co acquired Aton Pharma October 2004 for $85M + milestones; NDA 021743 approved October 6 2006 — 18-year bench-to-approval timeline from initial HPC hypothesis. The entire HDAC mechanism class, its epigenetic re-expression biology, and H360 reproductive toxicity are absent from all EHS platforms for CAS 149647-78-9.

Surface 1 — Merck Sharp & Dohme Corp Whitehouse Station NJ NDA 021743 Holder Zolinza US Commercialization AI

At Merck Sharp & Dohme Corp Whitehouse Station NJ (2000 Galloping Hill Rd, Kenilworth NJ 07033; Merck & Co Inc; NDA 021743 holder: MERCK NDA HISTORY: Merck acquired Aton Pharma Inc in October 2004 for $85M upfront + milestone payments; Aton Pharma, incorporated 2001 by Victoria Richon and Paul Marks, held the SAHA intellectual property developed at Columbia University/MSK; Merck accelerated NDA 021743 submission and received October 6 2006 FDA approval — 2-year timeline from acquisition to approval; ZOLINZA 100 mg CAPSULE: vorinostat 100 mg oral capsules (100 mg fill per gelatin capsule); patient takes 400 mg QD continuously with food (alternatively 300 mg QD × 3d/wk in select patients); SAHA LINEAR SCAFFOLD: at 264.32 g/mol, Zolinza capsules are essentially pure hydroxamic acid — the simplest pan-HDAC inhibitor; the HDAC1/2 dominant mechanism contrasts with HDAC6 effects (α-tubulin) and is entirely absent from Cority; CTCL REGULATORY: NDA 021743 was reviewed under Priority Review (CTCL is a rare orphan condition; ~3,000-5,000 new US cases/year); standard CTCL management: skin-directed therapies → systemic (HDAC inhibitors, mogamulizumab, bexarotene) → transplant; Cority: CAS 149647-78-9 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; forty-seventh mechanism class absent; first HDAC inhibitor absent; pan-HDAC zinc chelation absent; Classes I/II/IV absent; 52M oncology regulatory director 17yr).

Surface 2 — Merck Manufacturing Division Barceloneta Puerto Rico API Manufacturing Vorinostat Tablet Production AI

At Merck Manufacturing Division Barceloneta Puerto Rico (Road PR-2 Km 60.1, Barceloneta PR 00617; Municipio de Barceloneta; MERCK BARCELONETA MANUFACTURING: Merck Manufacturing Division's Barceloneta PR facility is one of Merck's principal US Territory API manufacturing sites; vorinostat API synthesis involves: (1) suberoyl chloride (octanedioyl dichloride) + aniline → suberoylanilide intermediate (N-phenyloctanediamide); (2) coupling of the mono-acid intermediate with hydroxylamine hydrochloride under standard hydroxamate esterification conditions → SAHA; the synthesis is relatively short (3-4 steps from commercially available starting materials — straightforward vs. multi-step syntheses of complex targets in this portfolio); MANUFACTURING OCCUPATIONAL EXPOSURE: vorinostat API crystalline powder; solubility ~400 µg/mL in DMSO/EtOH but poor aqueous solubility (~0.02 mg/mL); inhalation risk during weighing, blending, and encapsulation; NIOSH HD Category 1 handling precautions required (closed systems, engineering controls, respirators); H360 reproductive toxicity (developmental toxicity in animal studies; embryotoxic) — the H360 designation signals reproductive/developmental hazard beyond H361 (suspected); the H360 vs. H361 distinction is absent from VelocityEHS; MANUFACTURING NIOSH COMPLIANCE: NIOSH HD Category 1 requires OEB Band 5 controls (OEL <0.1 µg/m³) during manufacturing; Barceloneta manufacturing pharmacist exposure paradigm: weighing and blending vorinostat bulk powder → inhalation pathway; VelocityEHS: CAS 149647-78-9 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; forty-seventh mechanism class absent; first epigenetic enzyme drug absent; pan-HDAC Classes I/II/IV absent; SAHA hydroxamic acid zinc chelation absent; 47M pharmaceutical manufacturing specialist 13yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY NCT00094783 Discovery Institution CTCL Dermatology Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; Manhattan NY; MSK VORINOSTAT DISCOVERY CONTEXT: Memorial Sloan Kettering is the co-discovery institution for vorinostat (SAHA); Paul Marks MD (President of MSK 1980-1999, later President Emeritus) championed the hybrid polar compound program; Victoria Richon PhD (MSK Molecular Pharmacology program) led the medicinal chemistry optimization of SAHA; the SAHA program was MSK's first translational success in epigenetic pharmacology; NCT00094783 was a pivotal Phase 2 single-arm study at multiple sites including MSK; primary endpoint: overall response rate (ORR) by Severity Weighted Assessment Tool (SWAT); n=74; ORR 24.2% (CR 8.1%; PR 16.2%); median duration of response 168 days; pruritus relief in ~32% of patients (meaningful symptom benefit in a symptom-driven disease); MSK CTCL PHARMACIST: Memorial Sloan Kettering's dermatology oncology pharmacy prepares and dispenses Zolinza (vorinostat 100 mg capsules; 400 mg = 4 capsules QD with food); CTCL is a chronic disease requiring long-term oral HDAC inhibitor therapy; pharmacist occupational exposure risks include: receiving bulk vorinostat capsule stock, unit-dose repackaging for inpatient administration, compounding oral liquid formulations for patients unable to swallow intact capsules (SAHA suspension — extemporaneous formulation using 100 mg capsules opened into Ora-Sweet vehicle); H340 H350 H360 genotoxic/carcinogenic/reproductive hazard during extemporaneous preparation; EHS Insight: CAS 149647-78-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; forty-seventh mechanism class absent; first HDAC inhibitor absent; pan-HDAC Classes I/II/IV absent; H340 H350 H360 absent; NIOSH HD Cat 1 absent; 41F dermatology oncology pharmacist 12yr).

Integrating Glyphward into Vorinostat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vorinostat CAS 149647-78-9 monitoring data ingestion point — before Cority at Merck Sharp & Dohme Corp Whitehouse Station NJ, before VelocityEHS at Merck Manufacturing Division Barceloneta Puerto Rico, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H360 absent [10 pts]; FORTY-SEVENTH MECHANISM CLASS (HDAC INHIBITORS) + FIRST PAN-HDAC INHIBITOR EVER FDA APPROVED (NDA 021743 October 6 2006; first epigenetic enzyme-targeted cancer drug; established HDAC class for subsequent romidepsin/belinostat/panobinostat) + SAHA HYDROXAMIC ACID Zn2+ BIDENTATE CHELATION (Classes I HDAC1/2/3/8; Class IIa HDAC4/5/7/9; Class IIb HDAC6/10; Class IV HDAC11; sirtuin Class III NOT inhibited) + p21/p16 EPIGENETIC RE-EXPRESSION + HDAC6 α-TUBULIN/Hsp90 HYPERACETYLATION + VICTORIA RICHON/PAUL MARKS COLUMBIA-MSK 18-YEAR DISCOVERY + MERCK ATON PHARMA $85M 2004 ACQUISITION [5 pts]; Merck Whitehouse Station NJ + Merck Manufacturing Barceloneta PR + Memorial Sloan Kettering New York NY [3 pts]; HDAC class mechanism absent; first epigenetic enzyme drug absent; pan-HDAC Classes I/II/IV absent; H360 reproductive toxicity absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vorinostat(cas: str, reading_ugm3: float) -> dict:
    """Scan vorinostat with forty-seventh-class first-HDAC pan-zinc-chelation context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_seventh_mechanism_class_first_pan_hdac_inhibitor_ever_saha_hydroxamic_acid_zn2_chelation_hdac1_hdac6_classes_i_ii_iv_ctcl_orr_24_2_nda_021743_victoria_richon_paul_marks_merck"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_seventh_mechanism_class,
    #                    first_hdac_inhibitor_ever,
    #                    first_epigenetic_enzyme_cancer_drug,
    #                    pan_hdac_classes_i_ii_iv,
    #                    saha_zn2_bidentate_chelation,
    #                    h340_h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_vorinostat("149647-78-9", 0.00041))
    print(r)
    # {'hd_category': 1, 'forty_seventh_mechanism_class': True,
    #  'first_hdac_inhibitor_ever': True,
    #  'first_epigenetic_enzyme_cancer_drug': True,
    #  'pan_hdac_classes_i_ii_iv': True,
    #  'saha_zn2_bidentate_chelation': True,
    #  'h340_h350_h360_absent': True}